<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this pilot clinical study was to assess the safety, technical feasibility, pharmacokinetic (PK) profile and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response of DC Bead™ with irinotecan (DEBIRI™) delivered by intra-arterial embolisation for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Eleven patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> burden &lt;30% of liver volume, adequate haematological, liver and renal function, performance status of &lt;2 were included in this study </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received up to 4 sessions of TACE with DEBIRI at 3-week intervals </plain></SENT>
<SENT sid="3" pm="."><plain>Feasibility of the procedure, safety and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response were assessed after each cycle </plain></SENT>
<SENT sid="4" pm="."><plain>PK was measured after the first cycle </plain></SENT>
<SENT sid="5" pm="."><plain>Patients were followed up to 24 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>Only mild to moderate adverse events were observed </plain></SENT>
<SENT sid="7" pm="."><plain>DEBIRI is a technically feasibile procedure; no technical complications were observed </plain></SENT>
<SENT sid="8" pm="."><plain>Average Cmax for irinotecan and SN-38 was 194 ng/ml and 16.7 ng/ml, respectively, with average t½ of 4.6 h and 12.4 h following administration of DEBIRI </plain></SENT>
<SENT sid="9" pm="."><plain>Best overall response during the study showed disease control in 9 patients (2 patients with partial response and 7 with stable disease, overall response rate of 18%) </plain></SENT>
<SENT sid="10" pm="."><plain>Our study shows that transarterial chemoembolisation with irinotecan-loaded DC beads (DEBIRI) is safe, technically feasible and effective with a good PK profile </plain></SENT>
</text></document>